<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="1-part\PMC6692539\results\search\disease\results.xml">
  <result pre="Commentary, Meeting Report How to assess the effectiveness of nasal" exact="influenza" post="vaccines? Role and measurement of sIgA in mucosal secretions"/>
  <result pre="of mucosal immunity. Mucosally delivered vaccines, such as live attenuated" exact="influenza" post="vaccine (LAIV), are able to mimic natural infection without"/>
  <result pre="the advantages and limitations of their use. enzyme�?linked immunosorbent assay" exact="influenza" post="vaccines influenza virus mucosal immunity secretory IgAs fig-count: table-count:"/>
  <result pre="and limitations of their use. enzyme�?linked immunosorbent assay influenza vaccines" exact="influenza" post="virus mucosal immunity secretory IgAs fig-count: table-count: page-count: word-count:"/>
  <result pre="TrombettaC, ManiniI, MontomoliE. How to assess the effectiveness of nasal" exact="influenza" post="vaccines? Role and measurement of sIgA in mucosal secretions."/>
  <result pre="disease with high morbidity and mortality which is caused by" exact="influenza" post="viruses of types A and B.1, 2 Seasonal influenza"/>
  <result pre="by influenza viruses of types A and B.1, 2 Seasonal" exact="influenza" post="epidemics are estimated to result in 3�?5 million cases"/>
  <result pre="IgG antibodies.3 Figure 1 Simplified scheme of immune responses following" exact="influenza" post="virus infection of the upper respiratory tract with focus"/>
  <result pre="to the mucus by diffusion and provide protection against homologous" exact="influenza" post="viruses. dIgA are actively transcytosed across epithelial cells via"/>
  <result pre="cells via pIgR and provide protection against homologous and heterologous" exact="influenza" post="viruses. dIgA can bind to newly synthesized viral proteins"/>
  <result pre="immunity, also the cell�?mediated immune (CMI) response is activated after" exact="influenza" post="infection. Unlike humoral response, capable of neutralizing activity, CMI"/>
  <result pre="of antigen�?presenting cells (APCs), such as dendritic cells (DCs) and" exact="influenza" post="antigens, induce the differentiation of naïve B cells into"/>
  <result pre="after infection. sIgA have a pivotal role in protecting against" exact="influenza" post="infection of the upper respiratory mucosal surfaces, since they"/>
  <result pre="infection which support its additional important role in protection against" exact="influenza" post="virus re�?infections.18 Along with IgA, IgM antibodies are also"/>
  <result pre="in mice which has shown that IgM antibodies can neutralize" exact="influenza" post="viruses in the presence of complement just as well"/>
  <result pre="as well as IgG antibodies.19 2.4 IgA immune responses upon" exact="influenza" post="virus infection of the mucosa of the upper respiratory"/>
  <result pre="pIgA.29 3 IgA IMMUNE RESPONSE UPON INFLUENZA VACCINATION Conventional inactivated" exact="influenza" post="vaccines (IIVs), generally delivered through subcutaneous or intramuscular injection,"/>
  <result pre="the most efficient, valuable, and low�?cost tools to effectively reduce" exact="influenza" post="virus infections and subsequently morbidity and mortality.35 This parental"/>
  <result pre="wide cross�?protection activity. This represents a limit for conventional inactivated" exact="influenza" post="vaccines in conferring full protection against infection.36 While natural"/>
  <result pre="heterosubtypic responses, the immunity induced by parenterally application of inactivated" exact="influenza" post="vaccines is generally virus subtype�?specific.37 In pre�?immunized subjects, the"/>
  <result pre="antibodies could be elicited by intranasal vaccination with live attenuated" exact="influenza" post="vaccines (LAIV). Live attenuated influenza vaccines is administered as"/>
  <result pre="intranasal vaccination with live attenuated influenza vaccines (LAIV). Live attenuated" exact="influenza" post="vaccines is administered as a nasal spray and contains"/>
  <result pre="a nasal spray and contains a cold�?adapted (ca) live attenuated" exact="influenza" post="virus which, in contrast to wild�?type viruses, is able"/>
  <result pre="onwards, the use of Russian LAIV for the prophylaxis of" exact="influenza" post="has been widely extended to all age groups including"/>
  <result pre="IgA from the respiratory tract of mice immunized with live" exact="influenza" post="virus has been seen to provide protection in naive"/>
  <result pre="studies conducted on different age cohorts throughout the world.49 After" exact="influenza" post="LAIV administration, as well as natural infection, sIgA are"/>
  <result pre="vaccine strains or in children with underlying diseases such as" exact="asthma" post="have shown a higher efficiency in comparison to IIV,"/>
  <result pre="was provided by Q�?LAIV compared to IIV toward a drifted" exact="influenza" post="B strain. Data obtained from the US reported an"/>
  <result pre="reported an apparent lack of LAIV effectiveness in the 2015/2016" exact="influenza" post="season, especially toward A/H1N1 vaccine component. Such results have"/>
  <result pre="64 but without causing the signs and symptoms associated with" exact="influenza" post="illness.49 Nowadays, intranasal vaccination against influenza is mainly made"/>
  <result pre="and symptoms associated with influenza illness.49 Nowadays, intranasal vaccination against" exact="influenza" post="is mainly made up through ca LAIVs. However, other"/>
  <result pre="include the following: intranasal vaccinations using inactivated whole or split" exact="influenza" post="vaccines,65, 66 sublingual administration of adjuvanted influenza vaccines,67 and"/>
  <result pre="whole or split influenza vaccines,65, 66 sublingual administration of adjuvanted" exact="influenza" post="vaccines,67 and novel types of LAIVs, for example, formulated"/>
  <result pre="IgA CONTENT IN TEST SAMPLES According to the type of" exact="influenza" post="vaccine used and the route of administration, specific compartments"/>
  <result pre="which are still considered as the gold standard in assessing" exact="influenza" post="vaccine immunogenicity, is generally lower after intranasal vaccination than"/>
  <result pre="couple of laboratory tests that can be used to assess" exact="influenza" post="antibody levels, the enzyme�?linked immunosorbent assay (ELISA) is the"/>
  <result pre="different classes of antibodies that are able to bind to" exact="influenza" post="virions or purified HA proteins.70 Many different protocols and"/>
  <result pre="based on the same principle. Generally, HA protein or whole" exact="influenza" post="virus is pre�?adsorbed to the wells of an ELISA"/>
  <result pre="described elsewhere.73 In brief, ELISA plates are coated with an" exact="influenza" post="antigen (preferably purified HA) and a capture antibody (anti�?human"/>
  <result pre="protein content in the samples (Figure 2). The determination of" exact="influenza" post="HA�?specific IgA with respect to total protein generally proves"/>
  <result pre="will be added to the coated plate together with the" exact="influenza" post="antigen, and the background signal will be used to"/>
  <result pre="been shown in a previous pediatric study with LAIV that" exact="influenza" post="virus–specific salivary IgA levels correlated with serum HI responses,76"/>
  <result pre="approach to evaluate the immunogenicity of LAIVs, IIVs, or recombinant" exact="influenza" post="vaccines (eg rHA) in inducing selective anti�?influenza antibodies with"/>
  <result pre="influenza vaccines (eg rHA) in inducing selective anti�?influenza antibodies with" exact="influenza" post="virus–neutralizing potential. Beside classical ELISA�?based and NT assays specific"/>
  <result pre="virus–neutralizing potential. Beside classical ELISA�?based and NT assays specific anti�?HA" exact="influenza" post="antibodies, there are newer assays with increased precision and"/>
  <result pre="the simultaneous detection of antibodies against the Newcastle disease and" exact="avian influenza" post="virus and have shown that the Luminex XMAP�?based assay"/>
  <result pre="simultaneous detection of antibodies against the Newcastle disease and avian" exact="influenza" post="virus and have shown that the Luminex XMAP�?based assay"/>
  <result pre="assay has been up to 1024 times more sensitive for" exact="avian influenza" post="virus antibody detection compared to the conventional ELISA assay."/>
  <result pre="has been up to 1024 times more sensitive for avian" exact="influenza" post="virus antibody detection compared to the conventional ELISA assay."/>
  <result pre="6 CONCLUSIONS Influenza vaccines elicit protective immunity before a new" exact="influenza" post="virus variant is able to spread; they therefore constitute"/>
  <result pre="a primary protection tool. Although the main protective effectors against" exact="influenza" post="virus infection are CTLs, IgG, and IgA located in"/>
  <result pre="distribution. For these reasons, its expanded use could increase the" exact="influenza" post="vaccination coverage globally. Furthermore, it may represent a favorable"/>
  <result pre="recent years to develop novel intranasally administered vaccines to promote" exact="influenza" post="virus�?specific sIgA,30, 88 which, as has been widely reported,"/>
  <result pre="of vaccine efficacy or effectiveness in the field, as currently" exact="influenza" post="vaccine efficacy is traditionally assessed by means of serological"/>
  <result pre="measurement of sIgA in mucosal secretions for the evaluation of" exact="influenza" post="vaccine efficacy or effectiveness and, in addition, also of"/>
  <result pre="process. References REFERENCES 1GlezenWP. Serious morbidity and mortality associated with" exact="influenza" post="epidemics. Epidemiol Rev. 1982;4:25�?44.6754408 2https://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal).Accessed 20 August 2018. 3BrandtzagP,"/>
  <result pre="ClementsML. The systemic and mucosal immune response of humans to" exact="influenza" post="virus. Curr Topics Microbial Immun. 1989;146:107�?116. 6ItoR, OzakiYA, YoshikawaT,"/>
  <result pre="of the respiratory tract of vaccinated mice in preventing lethal" exact="influenza" post="pneumonia. Vaccine. 2003;21:2362�?2371.12744867 7SunJ, BracialeTJ. Role of T cell"/>
  <result pre="7SunJ, BracialeTJ. Role of T cell immunity in recovery from" exact="influenza" post="virus infection. Curr Opin Virol. 2013;3:425�?429.23721865 8DohertyPC, KelsoA. Towards"/>
  <result pre="Curr Opin Virol. 2013;3:425�?429.23721865 8DohertyPC, KelsoA. Towards a broadly protective" exact="influenza" post="vaccine. J Clin Invest. 2008;118:3273�?3275.18802488 9WoofJM, MesteckyJ. Mucosal immunoglobulins."/>
  <result pre="neutralizing antibody levels in nasal washings from men infected with" exact="influenza" post="virus. JAMA. 1970;211:1157�?1161.5466966 12WrightPF, MurphyBR, KervinaM, LawrenceEM, PhelanMA, KarzonDT."/>
  <result pre="KervinaM, LawrenceEM, PhelanMA, KarzonDT. Secretory immunological response after intranasal inactivated" exact="influenza" post="A virus vaccinations: evidence for immunoglobulin A memory. Infect"/>
  <result pre="1983;40:1092�?1095.6852914 13BrokstadKA, CoxRJ, ErikssonJC, OlofssonJ, JonssonR, DavidssonA. High prevalence of" exact="influenza" post="specific antibody secreting cells in nasal mucosa. Scand J"/>
  <result pre="antigen�?specific nasal secretory IgA levels and serum IgG levels after" exact="influenza" post="infection in adults. Influenza Other Respir Viruses. 2012;6:369�?403. 15van"/>
  <result pre="2012;6:369�?403. 15van RietE, AinaiA, SuzukiT, HasegawaH. Mucosal IgA responses in" exact="influenza" post="virus infections; thoughts for vaccine design. Vaccine. 2012;30:5893�?5900.22835738 16KokTW,"/>
  <result pre="CostabileM, TannockGA, LiP. Colocalization of intracellular specific IgA (icIgA) with" exact="influenza" post="virus in patients' nasopharyngeal aspirate cells. J Virol Methods."/>
  <result pre="cells. J Virol Methods. 2018;252:8�?14.29102516 17TamuraS, KurataT. Defense mechanisms against" exact="influenza" post="virus infection in the respiratory tract mucosa. Jpn J"/>
  <result pre="Comparison of the immune response to inactivated and live, attenuated" exact="influenza" post="vaccines. Scand J Immunol. 2004;59:1�?15.14723616 19SkountzouI, SatyabhamaL, StavropoulouA, et"/>
  <result pre="the quaternary structure of human secretory IgA to neutralization of" exact="influenza" post="virus. Proc Natl Acad Sci USA. 2015;112:7809�?7814.26056267 26MazanecMB, KaetzelCS,"/>
  <result pre="WrightPF. Role of IgA versus IgG in the control of" exact="influenza" post="viral infection in the murine respiratory tract. J Immunol."/>
  <result pre="virus neutralization on human upper respiratory mucosa after intranasal inactivated" exact="influenza" post="vaccine administration. Hum Vaccin Immunother. 2018;14(6):1351–1361.29425074 29RenegarKB, JacksonGD, MesteckyJ."/>
  <result pre="antibody. PLoS Pathog. 2019;15:e1007427.30605488 32TaylorHP, DimmockNJ. Mechanism of neutralization of" exact="influenza" post="virus by secretory IgA is different from that of"/>
  <result pre="or IgG. J Exp Med. 1985;161:198�?209.2981953 33ArmstrongSJ, DimmockNJ. Neutralization of" exact="influenza" post="virus by low concentrations of hemagglutinin�?specific polymeric immunoglobulin A"/>
  <result pre="characteristics of secretory IgA antibodies elicited by mucosal vaccines against" exact="influenza" post="virus. Vaccine. 2017;35:5297�?5302.28780981 35GianchecchiE, TrombettaC, PiccirellaS, MontomoliE. Evaluating influenza"/>
  <result pre="against influenza virus. Vaccine. 2017;35:5297�?5302.28780981 35GianchecchiE, TrombettaC, PiccirellaS, MontomoliE. Evaluating" exact="influenza" post="vaccines: progress and perspectives. Future Virology. 2016;11:379�?393. 36TamuraS. Studies"/>
  <result pre="Virology. 2016;11:379�?393. 36TamuraS. Studies on the usefulness of intranasal inactivated" exact="influenza" post="vaccines. Vaccine. 2010;28:6393�?6397.20493820 37MorokuttiA, MusterT, FerkoB. Intranasal vaccination with"/>
  <result pre="Vaccine. 2010;28:6393�?6397.20493820 37MorokuttiA, MusterT, FerkoB. Intranasal vaccination with a replication�?deficient" exact="influenza" post="virus induces heterosubtypic neutralising mucosal IgA antibodies in humans."/>
  <result pre="MinuseE, AndersonG. Laboratory and clinical characteristics of attenuated strains of" exact="influenza" post="virus. Bull World Health Organ. 1969;41:589�?594.5309481 39SlepushkinAN, DukovaVS, KalegaevaVA,"/>
  <result pre="KaganAN, TemriukEE. Results of studying the effectiveness of a live" exact="influenza" post="vaccine for peroral use on preschool and schoolchildren. Zh"/>
  <result pre="40RudenkoL, YeolekarL, KiselevaI, Isakova�?SivakI. Development and approval of live attenuated" exact="influenza" post="vaccines based on Russian master donor viruses: Process challenges"/>
  <result pre="al. Rationale for vaccination with trivalent or quadrivalent live attenuated" exact="influenza" post="vaccines: protective vaccine efficacy in the ferret model. PLoS"/>
  <result pre="the ferret model. PLoS ONE. 2018;13(12):e0208028.30507951 42CarterNJ, CurranMP. Live attenuated" exact="influenza" post="vaccine (FluMist®; Fluenz™): a review of its use in"/>
  <result pre="a review of its use in the prevention of seasonal" exact="influenza" post="in children and adults. Drugs. 2011;71:1591�?1622.21861544 43TamuraS�?I, FunatoH, HirabayashiY,"/>
  <result pre="adults. Drugs. 2011;71:1591�?1622.21861544 43TamuraS�?I, FunatoH, HirabayashiY, et al. Cross�?protection against" exact="influenza" post="A virus infection by passively transferred respiratory tract IgA"/>
  <result pre="J Immunol. 1991;21:1337�?1344.1646112 44AsahiY, YoshikawaT, WatanabeI, et al. Protection against" exact="influenza" post="virus infection in polymeric Ig receptor knockout mice immunized"/>
  <result pre="2002;168:2930�?2938.11884464 45NguyenHH, van GinkelFW, VuHL, McGheeJR, MesteckyJ. Heterosubtypic immunity to" exact="influenza" post="A virus infection requires B cells but not CD8+"/>
  <result pre="Dis. 2001;183:368�?376.11133367 46RenegarKB, SmallPAJr. Passive transfer of local immunity to" exact="influenza" post="virus infection by IgA antibody. J Immunol. 1991;146:1972�?1978.2005388 47RenegarKB,"/>
  <result pre="antibodies in lungs of mice after intragastric administration of inactivated" exact="influenza" post="virus vaccines. J Gen Virol. 1988;69:2779�?2784.3183627 49RappuoliR, Del GiudiceG."/>
  <result pre="al. Evaluation of trivalent, live, cold�?adapted (CAIV�?T) and inactivated (TIV)" exact="influenza" post="vaccines in prevention of virus infection and illness following"/>
  <result pre="virus infection and illness following challenge of adults with wild�?type" exact="influenza" post="A (H1N1), A (H3N2), and B viruses. Vaccine. 1999;18:899�?906.10580204"/>
  <result pre="al. Efficacy of vaccination with live attenuated, cold�?adapted, trivalent, intranasal" exact="influenza" post="virus vaccine against a variant (A/Sydney) not contained in"/>
  <result pre="VertruyenA, ArísteguiJ, et al. Superior relative efficacy of live attenuated" exact="influenza" post="vaccine compared with inactivated influenza vaccine in young children"/>
  <result pre="relative efficacy of live attenuated influenza vaccine compared with inactivated" exact="influenza" post="vaccine in young children with recurrent respiratory tract infections."/>
  <result pre="Comparison of the efficacy and safety of live attenuated cold�?adapted" exact="influenza" post="vaccine, trivalent, with trivalent inactivated influenza virus vaccine in"/>
  <result pre="of live attenuated cold�?adapted influenza vaccine, trivalent, with trivalent inactivated" exact="influenza" post="virus vaccine in children and adolescents with asthma. Pediatr"/>
  <result pre="2006;25:860�?869.17006278 54McLeanHQ, CaspardH, GriffinMR, et al. Effectiveness of live attenuated" exact="influenza" post="vaccine and inactivated influenza vaccine in children during the"/>
  <result pre="et al. Effectiveness of live attenuated influenza vaccine and inactivated" exact="influenza" post="vaccine in children during the 2014–2015 season. Vaccine. 2017;35:2685�?2693.28408121"/>
  <result pre="2017;35:2685�?2693.28408121 55JeffersonT, Di PietrantonjC, RivettiA, et al. Vaccines for preventing" exact="influenza" post="in healthy adults. Cochrane Database Syst Rev. 2010;(7): CD001269."/>
  <result pre="Cochrane Database Syst Rev. 2014;3:CD001269. 56PebodyR, McMenaminJ, NohynekH. Live attenuated" exact="influenza" post="vaccine (LAIV): recent effectiveness results from the USA and"/>
  <result pre="Child. 2018;103:101�?105.28855230 57PebodyR, WarburtonF, EllisJ, et al. Effectiveness of seasonal" exact="influenza" post="vaccine for adults and children in preventing laboratory�?confirmed influenza"/>
  <result pre="seasonal influenza vaccine for adults and children in preventing laboratory�?confirmed" exact="influenza" post="in primary care in the United Kingdom: 2015/16 end�?of�?season"/>
  <result pre="SundmanJ, JokinenJ. Effectiveness of the live attenuated and the inactivated" exact="influenza" post="vaccine in two�?year�?olds – A nationwide cohort study Finland,"/>
  <result pre="influenza vaccine in two�?year�?olds – A nationwide cohort study Finland," exact="influenza" post="season 2015/16. Euro Surveill. 2016;21, 1�?8. 59MohnK g�?i, BredholtG,"/>
  <result pre="al. Longevity of B�?cell and T�?cell responses after live attenuated" exact="influenza" post="vaccination in children. J Infect Dis. 2015;211:1541�?1549.25425696 60SridharS, BrokstadKA,"/>
  <result pre="BrokstadKA, CoxRJ. Influenza vaccination strategies: comparing inactivated and live attenuated" exact="influenza" post="vaccines. Vaccines. 2015;3(2):373�?389.26343192 61WagnerDK, ClementsML, ReimerCB, SnyderM, NelsonDL, MurphyBR."/>
  <result pre="immunoglobulin G antibody responses after administration of live and inactivated" exact="influenza" post="A vaccine indicates that nasal wash immunoglobulin G is"/>
  <result pre="for distinct immune responses to trivalent inactivated and live attenuated" exact="influenza" post="vaccines. J Cell Physiol. 2019;234:5196�?5202.30203415 63BeyerWE, PalacheAM, de JongJC,"/>
  <result pre="Cell Physiol. 2019;234:5196�?5202.30203415 63BeyerWE, PalacheAM, de JongJC, OsterhausAD. Cold�?adapted live" exact="influenza" post="vaccine versus inactivated vaccine: systemic vaccine reactions, local and"/>
  <result pre="FerkoB, ByunY�?H, et al. Sublingual immunization with a live attenuated" exact="influenza" post="a virus lacking the nonstructural protein 1 induces broad"/>
  <result pre="virus vaccine induces a broad spectrum of heterosubtypic immunity against" exact="influenza" post="A virus infection in mice. Vaccine. 2003;21:3212�?3218.12804850 66CoxRJ, HovdenA�?O,"/>
  <result pre="and protective efficacy of vaccination with inactivated split and whole" exact="influenza" post="virus vaccines in BALB/c mice. Vaccine. 2006;10(24):6585�?6587. 67GalloriniS, TacconeM,"/>
  <result pre="67GalloriniS, TacconeM, BonciA, et al. Sublingual immunization with a subunit" exact="influenza" post="vaccine elicits comparable systemic immune response as intramuscular immunization,"/>
  <result pre="WolschekM, SeipeltJ, MusterT. Phase I/II trial of a replication�?deficient trivalent" exact="influenza" post="virus vaccine lacking NS1. Vaccine. 2013;31:6194�?6200.24183981 69CoxJR, BrokstadKA, OgraP."/>
  <result pre="Comparison of the Immune response to inactivated and live, attenuated" exact="influenza" post="vaccine. Scand J Immunol. 2003;59:1�?15. 70KatzJM, HancockK, XuX. Serologic"/>
  <result pre="Scand J Immunol. 2003;59:1�?15. 70KatzJM, HancockK, XuX. Serologic assays for" exact="influenza" post="surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect"/>
  <result pre="71MurphyBR, PhelanMA, NelsonDL. Hemagglutinin�?specific enzyme�?linked immunosorbent assay for antibodies to" exact="influenza" post="A and B. J Clin Virol. 1981;43:241�?243. 72El�?MadhunAS, CoxRJ,"/>
  <result pre="priming on the IgG and IgA subclass responses after parenteral" exact="influenza" post="vaccination. J Infect Dis. 1999;180:1356�?1360.10479172 73ManentiA, TeteSM, MohonG, et"/>
  <result pre="IgG subclass and IgA responses in children and adults after" exact="influenza" post="vaccination. Vaccine. 2017;35:191�?198.27789145 74AinaiA, TamuraS�?I, SuzukiT, et al. Intranasal"/>
  <result pre="TamuraS�?I, SuzukiT, et al. Intranasal vaccination with an inactivated whole" exact="influenza" post="virus vaccine induces strong antibody responses in serum and"/>
  <result pre="Eng J. 2010;4:271�?278.21625379 76MohnK�?I, BrokstadKA, PathiranaRD, et al. Live attenuated" exact="influenza" post="vaccine in children induces B�?cell responses in tonsils. J"/>
  <result pre="2016;214:722�?731.27247344 77MohnKG�?I, SmithI, SjursenH, CoxJC. Immune responses after live attenuated" exact="influenza" post="vaccination. Hum Vacc Immunother. 2018;14:571�?578. 78HowardKM, SabarthN, Savidis�?DachoH, et"/>
  <result pre="SteinC, et al. Localized mucosal response to intranasal live attenuated" exact="influenza" post="vaccine in adults. J Infect Dis. 2013;207:115�?124.23087433 80GriffinSM, ConverseRR,"/>
  <result pre="the simultaneous detection of antibodies to Newcastle disease virus and" exact="avian influenza" post="virus. Poult Sci. 2019;98:1494�?1499.30476286 82SindoniD, La FauciV, SqueriR, et"/>
  <result pre="simultaneous detection of antibodies to Newcastle disease virus and avian" exact="influenza" post="virus. Poult Sci. 2019;98:1494�?1499.30476286 82SindoniD, La FauciV, SqueriR, et"/>
  <result pre="Comparison between a conventional subunit vaccine and the MF59�?adjuvanted subunit" exact="influenza" post="vaccine in the elderly: an evaluation of the safety,"/>
  <result pre="Hyg. 2009;50:121�?126.20099444 83SqueriR, RisoR, FacciolàA, et al. Management of two" exact="influenza" post="vaccination campaign in health care workers of a university"/>
  <result pre="Italy. Ann Ig. 2017;29:223�?231.28383614 84AdaGL, JonesPD. The immune response to" exact="influenza" post="infection. Curr Top Microbiol Immunol. 1986;128:1�?54.3533447 85BelzGT, WodarzD, DiazG,"/>
  <result pre="Top Microbiol Immunol. 1986;128:1�?54.3533447 85BelzGT, WodarzD, DiazG, NowakMA, DohertyPC. Compromised" exact="influenza" post="virus�?specific CD8(+)�?T�?cell memory in CD4(+)�?T�?cell�?deficient mice. J Virol. 2002;76:12388�?12393.12414983"/>
  <result pre="2005;5(12):905�?916.16239901 88MoldoveanuZ, ClementsML, PrinceSJ, MurphyBR, MesteckyJ. Human immune responses to" exact="influenza" post="virus vaccines administered by systemic or mucosal routes. Vaccine."/>
  <result pre="ManiniI, GianchecchiE. Immunogenicity and safety of the new inactivated quadrivalent" exact="influenza" post="vaccine Vaxigrip Tetra: preliminary results in children &amp;gt; months"/>
 </snippets>
</snippetsTree>
